Pacific Biosciences Of California (PACB) Non-Current Deferred Tax Liability (2021 - 2022)

Pacific Biosciences Of California (PACB) recorded quarterly Non-Current Deferred Tax Liability of $835000.0 in Q4 2022, little changed quarter-over-quarter from $838000.0 in Q4 2021, and little changed on a YoY basis from $838000.0 in Q4 2021.

Pacific Biosciences Of California (PACB) Non-Current Deferred Tax Liability (2021 - 2022) Analysis & Trends

Pacific Biosciences Of California's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $835000.0 for Q4 2022.

  • In Q4 2022, Non-Current Deferred Tax Liability changed 0.36% year-over-year to $835000.0; the TTM figure through Dec 2022 stood at $835000.0 (changed 0.36% YoY), while the FY2022 annual figure was $835000.0, changed 0.36% from the prior year.
  • Non-Current Deferred Tax Liability was $835000.0 for Q4 2022 at Pacific Biosciences Of California, roughly flat from $838000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $838000.0 in Q4 2021 to a low of $835000.0 in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 Pacific Biosciences Of California 426.62 Mn 150.66 Mn 12.84 Mn

Historic Data

Download Data
DateValue
Dec 31, 2022 835,000.00
Dec 31, 2022 835,000.00
Dec 31, 2021 838,000.00
Dec 31, 2021 838,000.00